We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-2.48%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$812B
AUM Growth
-$55.8B
Cap. Flow
-$18.8B
Cap. Flow %
-2.31%
Top 10 Hldgs %
32.22%
Holding
3,109
New
91
Increased
2,002
Reduced
738
Closed
70

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$3.81B
2
XYZ
Block Inc
XYZ
+$1.46B
3
ACN icon
Accenture
ACN
+$1.23B
4
GILD icon
Gilead Sciences
GILD
+$1.15B
5
VLO icon
Valero Energy
VLO
+$1.05B

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$4.61B
2
META icon
Meta Platforms (Facebook)
META
+$2.06B
3
TSLA icon
Tesla
TSLA
+$1.81B
4
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$1.72B
5
AMZN icon
Amazon
AMZN
+$1.59B

Sector Composition

Rank Sector Weight
1 Technology 30.44%
2 Healthcare 13.92%
3 Financials 12.3%
4 Consumer Discretionary 10.98%
5 Communication Services 9.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MURA
2951
DELISTED
Mural Oncology
MURA
$34K ﹤0.01%
26,905
SGHT icon
2952
Sight Sciences
SGHT
$461M
$34K ﹤0.01%
13,756
CCLD icon
2953
CareCloud
CCLD
$105M
$33K ﹤0.01%
23,700
CRBU icon
2954
Caribou Biosciences
CRBU
$166M
$33K ﹤0.01%
35,848
LCTX icon
2955
Lineage Cell Therapeutics
LCTX
$271M
$33K ﹤0.01%
72,398
-35,806
-33% -$21K
MGNX icon
2956
MacroGenics
MGNX
$270M
$33K ﹤0.01%
25,652
-460,335
-95% -$1.2M
NMRA icon
2957
Neumora Therapeutics
NMRA
$322M
$33K ﹤0.01%
32,548
AIRJW
2958
AirJoule Technologies Warrant
AIRJW
$98.6M
$32K ﹤0.01%
56,154
DARE icon
2959
Dare Bioscience
DARE
$20.2M
$31K ﹤0.01%
10,491
FATE icon
2960
Fate Therapeutics
FATE
$311M
$31K ﹤0.01%
38,049
PAYS icon
2961
Paysign
PAYS
$723M
$31K ﹤0.01%
14,600
+3,500
+32% +$9.34K
REKR icon
2962
Rekor Systems
REKR
$98.5M
$31K ﹤0.01%
34,757
+1,594
+5% +$2.52K
TNGX icon
2963
Tango Therapeutics
TNGX
$4.32B
$31K ﹤0.01%
22,252
+1,254
+6% +$3.08K
TPIC
2964
DELISTED
TPI Composites
TPIC
$31K ﹤0.01%
37,404
WALD icon
2965
Waldencast
WALD
$169M
$31K ﹤0.01%
+10,173
New +$32.9K
BRN icon
2966
Barnwell Industries
BRN
$13.9M
$30K ﹤0.01%
18,200
PDSB icon
2967
PDS Biotechnology
PDSB
$13.1M
$30K ﹤0.01%
24,900
NPWR icon
2968
NET Power
NPWR
$143M
$28K ﹤0.01%
+10,310
New +$72.8K
ZURA icon
2969
Zura Bio
ZURA
$543M
$27K ﹤0.01%
20,830
CSTE icon
2970
Caesarstone
CSTE
$105M
$26K ﹤0.01%
+10,602
New +$39.7K
INO icon
2971
Inovio Pharmaceuticals
INO
$92.8M
$26K ﹤0.01%
+15,601
New +$31.3K
LVO icon
2972
LiveOne
LVO
$56.9M
$26K ﹤0.01%
3,595
FRGE
2973
DELISTED
Forge Global Holdings
FRGE
$25K ﹤0.01%
2,902
NOTE
2974
DELISTED
FiscalNote
NOTE
$25K ﹤0.01%
2,537
+904
+55% +$13.6K
LNAI
2975
Lunai Bioworks
LNAI
$10.4M
$25K ﹤0.01%
565

Similar funds

T. Rowe Price Associates's Q1 2025 Portfolio in Review

As of Q1 2025, T. Rowe Price Associates held 3,109 positions worth $812B, down 6.4% from $867B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

T. Rowe Price Associates's Q1 2025 filing shows 91 new, 2,002 increased, 738 reduced and 70 closed positions. Its largest new stake was T. Rowe Price Value ETF: 8,943,567 shares worth $283M. The largest sale was NVIDIA, an estimated $4.61B.

By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 33% a quarter earlier, followed by Healthcare and Financials.

  • T. Rowe Price Associates's largest Q1 2025 buy was T. Rowe Price Value ETF: 8,943,567 shares worth $283M.
  • T. Rowe Price Associates added most to Broadcom in Q1 2025, an estimated $3.81B increase.
  • T. Rowe Price Associates's biggest Q1 2025 reduction was NVIDIA, cutting an estimated $4.61B.
  • T. Rowe Price Associates fully exited Summit Materials, Inc. Class A Common Stock in Q1 2025, selling an estimated $271M.
  • T. Rowe Price Associates's ten largest holdings make up 32% of its $812B portfolio in Q1 2025.
  • T. Rowe Price Associates opened 91 new positions and closed 70 in Q1 2025.
  • T. Rowe Price Associates's portfolio value fell 6.4% quarter-over-quarter to $812B.

Based on T. Rowe Price Associates's 13F filing for Q1 2025, filed 14 May 2025.